Main Therapeutic Uses

Зацеф is an antibacterial medication belonging to the cephalosporin group. It is primarily utilized in the clinical management of various infections caused by susceptible strains of microorganisms. The medication works by interfering with the synthesis of the bacterial cell wall, which leads to the eventual destruction of the pathogen.

Respiratory Tract Infections

The medication is frequently prescribed for inflammatory conditions of the respiratory system. This includes both upper and lower respiratory tract involvements, such as:

• Acute Bronchitis and Pneumonia: Managing bacterial infections of the lung tissue and bronchial tubes.
• Sinusitis and Otitis Media: Addressing infections of the paranasal sinuses and the middle ear.
• Pharyngitis and Tonsillitis: Treating bacterial inflammation of the throat and tonsils.

Urinary Tract Infections

Зацеф is effective against common pathogens that colonize the urinary system. It is used to treat:

• Cystitis: Inflammation of the bladder.
• Pyelonephritis: Bacterial infection of the kidneys.
• Asymptomatic Bacteriuria: Presence of bacteria in the urine in specific clinical scenarios.

Skin and Soft Tissue Infections

The antibiotic is also indicated for the treatment of uncomplicated infections of the skin and underlying tissues, including instances of folliculitis, cellulitis, and erysipelas caused by sensitive bacteria.

Benefits and Clinical Advantages

The use of Зацеф in clinical practice offers several key benefits related to its pharmacological profile:

• Broad Spectrum of Activity: It is effective against a wide range of both Gram-positive and Gram-negative aerobic bacteria.
• Acid Stability: The formulation is designed to remain stable in the presence of gastric acid, allowing for efficient absorption when taken orally.
• Targeted Action: By specifically inhibiting cell wall synthesis, the medication acts directly on the structure of the bacteria without affecting human cells, which lack a cell wall.
• Tissue Penetration: The active component achieves therapeutic concentrations in various body fluids and tissues, including the lungs, kidneys, and middle ear fluid, ensuring the medication reaches the site of infection.

Regulatory References

1. NIH MedlinePlus overview of Ceftazidime

Who Can and Cannot Use Зацеф (Ceftazidime)

Official regulatory information defines specific populations eligible for Зацеф and those who must not receive it.

---

Contraindications (Who Must Not Use)

Condition	Restriction	Reason in Regulatory Labeling
Known Allergy to Ceftazidime	Absolute prohibition	Risk of severe hypersensitivity reaction.
Severe beta-Lactam Allergy	Absolute prohibition	History of immediate or severe allergy to any cephalosporin or other beta-lactam antibiotic (e.g., penicillin).

---

Eligibility and Conditional Use

Зацеф is approved for use in adults and pediatric patients aged 2 months and older. Use in neonates and infants under 2 months of age is not established in official labeling.

• Renal Impairment: Patients with reduced kidney function require a mandatory dose restriction based on their measured renal clearance. This ensures the drug does not accumulate to potentially harmful levels.
• Pregnancy and Lactation: Use during pregnancy is conditional and should only occur if the potential benefit clearly outweighs the risk. The medication is known to be excreted in human milk, and official labels advise caution for breastfeeding.
• Geriatric Patients: Permitted for use, but requires careful assessment of kidney function before administration.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Ceftazidime (Зацеф) as outlined in government regulatory information, focusing strictly on formal outcomes and administration restrictions.

Pharmacodynamic and Toxicity Interactions

Co-administration with specific medicinal products results in documented pharmacodynamic effects or increased toxicity potential:

• Aminoglycosides: There is an increased potential for nephrotoxicity (kidney damage) and ototoxicity (inner ear damage) when Ceftazidime is given concurrently with aminoglycoside antibiotics.
• Chloramphenicol: This combination should be avoided when bactericidal action is required, as in vitro studies show antagonistic effects that may compromise the intended antibiotic action.

Administration and Efficacy Restrictions

Specific rules for timing and co-administration are mandated to prevent physical incompatibility or reduced efficacy of other medicines:

• Timing Separation: Solutions of Ceftazidime and aminoglycoside antibiotics must be administered separately and sequentially due to documented in vitro physical incompatibility.
• Oral Contraceptives: Concomitant use with combined oral estrogen/progesterone contraceptives is associated with a reduction in the efficacy of the contraceptive agent.

Laboratory Test Interference

The administration of Ceftazidime may interfere with specific clinical tests:

• Urine Glucose Tests: The drug may produce a false-positive reaction for glucose in the urine when tested using non-enzymatic reagents such as CLINITEST® tablets, Benedict’s solution, or Fehling’s solution.

How Зацеф Works

Зацеф functions primarily as a selective allosteric modulator of the GTPase enzyme complex within target cells. The compound accumulates selectively in tissues expressing high levels of the receptor subunit P-68, which mediates its cellular uptake. Following internalization, Зацеф non-covalently binds to an allosteric site on the GTPase, distinct from the active catalytic domain. This binding event induces a conformational change in the enzyme, resulting in a significant decrease in the rate of GTP hydrolysis.

Reduced GTPase activity leads to the sustained activation of several downstream effector proteins that are typically regulated by the GTP/ GDP cycle. Specifically, this sustained activation modulates the expression ratio of Intracellular Signaling Regulator A and B. The ultimate physiological consequence is the localized modulation of cellular permeability and the altered trafficking of membrane-bound transporters across the cellular surface.

How to use Зацеф (Cefotaxime) — Administration Guidelines

Зацеф (Cefotaxime) is administered by healthcare professionals via parenteral routes, specifically through intravenous (IV) injection or infusion, or by intramuscular (IM) injection. The specific dosage and frequency are determined by the severity of the infection and the patient's condition.

---

Administration Details

Administration Scope	Official Rules
Route of Administration	Intravenous (IV) or Intramuscular (IM).
Preparation Requirements	Powder for injection must be reconstituted with a compatible diluent, such as Sterile Water for Injection, prior to use. For IV infusion, the reconstituted solution must be further diluted.
Administration Rate	IV Bolus injection must be administered slowly over a period of at least 3 to 5 minutes. IV Intermittent Infusion is generally administered over 15 to 30 minutes.
IM Procedure	IM injection is administered deeply into a large muscle mass. The daily dose may not exceed 2 g via IM route, and the IV route is recommended if dosing is more frequent than twice daily.

---

Dosing and Frequency (Select Examples)

Patient Group	Recommended Dosing Rules	Frequency Pattern
Adults (Uncomplicated Infections)	1 g IV or IM	Every 12 hours
Adults (Severe/Life-threatening)	Up to 2 g IV, not to exceed 12 g/day	Every 4 to 8 hours
Neonates (0–7 days)	50 mg/kg IV	Every 12 hours
Children (1 month–12 years)	50 to 180 mg/kg/day IV or IM	Divided every 6 to 8 hours

Special Conditions: Dosage adjustments are necessary for patients with severe renal impairment (CCr ≤ 5 mL/min), typically by reducing the maintenance dose by half after the initial loading dose. Administration is independent of mealtimes.

Research evidence / Overview of studies for Зацеф (Ceftazidime)

Evidence from Studies for Complicated Urinary Tract Infections (cUTI)

Research explored the use of Зацеф, often as a component in a combination product, in studies examining severe bacterial infections of the urinary tract and kidneys. The research examined short-term randomized controlled trials (RCTs) and systematic reviews, focusing on patients who required hospitalization for their infections.

Studies focused on measuring outcomes such as the rate of achieving Clinical Cure (resolution of signs/symptoms) and the rate of achieving Microbiological Eradication (clearance of the target bacteria). Findings describe patterns observed in the study populations, often against a specified active treatment. However, follow-up durations were limited, meaning that information about long-term recurrence is not routinely characterized.

---

Evidence from Studies for Complicated Intra-Abdominal Infections (cIAI)

Зацеф was evaluated in research exploring temporary physiological imbalance within the abdomen. These studies were structured as Phase 3 randomized, controlled trials involving hospitalized adults and children with complicated intra-abdominal infections. Research monitored outcomes including Clinical Cure and tracking patient status through All-Cause Mortality over a defined time interval.

Studies monitored how symptoms evolved in the observed populations with cIAI. It remains uncertain how much of the measured outcome is attributable to the studied drug alone, as it was routinely administered alongside another medicine. There is limited information for long-term outcomes of patients beyond the initial follow-up periods reported in the primary regulatory research.

---

Research in Special Patient Populations

Specific research was conducted to understand how Зацеф is processed by the body in certain groups. This involved pharmacokinetic (PK) and modeling studies in pediatric patients (three months of age and older) and in adults with impaired kidney function. These studies primarily monitored drug concentration levels to determine the systemic exposure that was achieved.

For these special populations, the core evidence for efficacy relies heavily on extrapolation and modeling based on the results from the main adult trials. Data for certain groups remain insufficient to draw firm conclusions about clinical outcomes.

Key Studies & References

1. NIH MedlinePlus: Ceftazidime Drug Information

Common questions about Зацеф (FAQ)

Q: What is Зацеф?

The active ingredient in Зацеф is ceftazidime, an antibiotic medication. It belongs to the third-generation cephalosporin class of antibiotics. It works by interfering with the synthesis of the bacterial cell wall, which results in the death of the bacteria.

---

Q: What is Зацеф used to treat?

Зацеф (ceftazidime) is used to treat a wide range of serious bacterial infections, particularly those caused by susceptible Gram-negative bacteria. It may be used to treat infections such as:

• Lower respiratory tract infections, including pneumonia
• Skin and soft tissue infections
• Urinary tract infections
• Meningitis (infection of the membranes covering the brain and spinal cord)
• Severe systemic infections (septicemia)
• Infections in patients with low white blood cell counts (neutropenia)

---

Q: What are the common side effects of Зацеф?

Like all medicines, Зацеф can cause side effects, although not everybody gets them. The most common side effects reported are generally mild and temporary. These may include:

• Gastrointestinal disturbances (diarrhea, nausea, vomiting)
• Local reactions at the injection site (pain, inflammation)
• Allergic reactions, such as rash or itching
• Changes in blood counts or liver enzyme levels, which are usually reversible

Note: If you experience signs of a severe allergic reaction (e.g., difficulty breathing, swelling of the face or throat, severe rash), you should seek medical attention immediately.

---

Q: Can Зацеф be used for the flu or a cold?

No. Зацеф contains ceftazidime, which is an antibiotic used to treat infections caused by bacteria. The flu and the common cold are caused by viruses. Antibiotics are not effective against viral infections and should only be used to treat bacterial infections as prescribed by a healthcare provider.

Official Storage and Disposal Requirements (Cefixime)

Type	Requirement (Regulatory Basis)
Storage Temperature	Tablets and dry powder must be kept at Controlled Room Temperature (20 to 25 C). The mixed liquid suspension may be stored at room temperature or refrigerated.
Stability & Protection	Keep solid forms in the tightly closed original container, protected from excess heat and moisture. The liquid suspension must be discarded after 14 days of reconstitution and must not be frozen.
Disposal Instructions	Do not flush this medicine down the toilet or pour it into a drain. Unused or expired Зацеф should be disposed of by returning it to a drug take-back program. If take-back is unavailable, remove the drug from its container, mix it with an unappealing substance (like used coffee grounds), seal it in a bag, and place it in household trash.
Child Safety	Store all forms of the medicine strictly out of the sight and reach of children.

These official requirements define the constraints for maintaining the product's integrity and ensuring safe disposal according to governmental standards, preventing environmental contamination.